Antiviral activity of WIN 54954 in coxsackievirus B2 carrier state infected human myocardial fibroblasts

Heim, Albert; Pfetzing, Ute; Müller, Gudrun; Grumbach, Isabella M.

doi:10.1016/s0166-3542(97)00056-9

Cited by 13 publications

(7 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Therefore, the developed TM-PCR seems to be well optimised with a sensitivity of 100 copies per run, equivalent to 3800 copies/ml CSF. Moreover, very satisfactory results for the diagnosis of enterovirus aseptic meningitis compared to a highly sensitive nested-PCR protocol were achieved (Heim et al, 1998). This aspect may be more interesting in the diagnostic setting than ultimate sensitivity.…”

Section: Discussionmentioning

confidence: 93%

“…In vitro transcripts of the 5 non-coding region of coxsackievirus B3 (CVB3) Nancy strain were generated by cloning a PCR product using primers CX3M (Heim et al, 1998) and EntRev (5 -TTG-TCA-CCA-TAA-GCA-GCC-A-3 ; position 609-627 of CVB3 sequence; Fig. 1) into pCRII-plasmid (Invitrogen, San Diego, CA) according to the TA Cloning Kit's instructions (Invitrogen).…”

Section: In Vitro Transcribed Cvb3 Rnamentioning

confidence: 99%

“…Purified RNA solution (9 l) was subjected to a parallel study of enterovirus RNA detection by the TM-PCR assay and the established diagnostic 'in-house' nested RT-PCR assay (Heim et al, 1998). Diagnostic specificity was confirmed with 76 CSF samples of patients with encephalomyelitis disseminata.…”

Section: Diagnostic Samplesmentioning

confidence: 99%

See 2 more Smart Citations

Rapid routine detection of enterovirus RNA in cerebrospinal fluid by a one-step real-time RT-PCR assay

Dierssen

Rehren

Henke-Gendo

et al. 2008

Journal of Clinical Virology

Self Cite

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 93%

Section: In Vitro Transcribed Cvb3 Rnamentioning

confidence: 99%

See 1 more Smart Citation

Rapid routine detection of enterovirus RNA in cerebrospinal fluid by a one-step real-time RT-PCR assay

Dierssen

Rehren

Henke-Gendo

et al. 2008

Journal of Clinical Virology

Self Cite

View full text Add to dashboard Cite

“…Furthermore, binding of specific WIN molecules in the pocket results in an increase in protein rigidity and stabilizes the entire viral capsid against enzymatic degradation so that uncoating and release of viral RNA into the cytoplasm is prevented [ 45 , 46 , 47 ]. In the last 25 years many WIN based drugs have been tested regarding their inhibitory effects against different members of the picornavirus family such as rhinovirus [ 48 ], poliovirus [ 49 ], echovirus [ 50 ], and enterovirus [ 51 ]. WIN 54954, a broad-spectrum anti-picornaviral drug, was one of the first WIN compounds to be clinically tested.…”

Section: Pharmacologically Active Low Molecular Weight Substancesmentioning

confidence: 99%

“…WIN 54954, a broad-spectrum anti-picornaviral drug, was one of the first WIN compounds to be clinically tested. Its effectiveness against human rhinovirus, echovirus 9 and also enterovirus infections has been shown in vitro and in vivo [ 51 , 52 , 53 , 54 ]. In vitro studies demonstrated that WIN 54954 can reduce picornavirus titers by 1 to 2 orders of magnitude [ 51 , 52 ].…”

Section: Pharmacologically Active Low Molecular Weight Substancesmentioning

confidence: 99%

Pharmacological and Biological Antiviral Therapeutics for Cardiac Coxsackievirus Infections

et al. 2011

View full text Add to dashboard Cite

Subtype B coxsackieviruses (CVB) represent the most commonly identified infectious agents associated with acute and chronic myocarditis, with CVB3 being the most common variant. Damage to the heart is induced both directly by virally mediated cell destruction and indirectly due to the immune and autoimmune processes reacting to virus infection. This review addresses antiviral therapeutics for cardiac coxsackievirus infections discovered over the last 25 years. One group represents pharmacologically active low molecular weight substances that inhibit virus uptake by binding to the virus capsid (e.g., pleconaril) or inactivate viral proteins (e.g., NO-metoprolol and ribavirin) or inhibit cellular proteins which are essential for viral replication (e.g., ubiquitination inhibitors). A second important group of substances are interferons. They have antiviral but also immunomodulating activities. The third and most recently discovered group includes biological and cellular therapeutics. Soluble receptor analogues (e.g., sCAR-Fc) bind to the virus capsid and block virus uptake. Small interfering RNAs, short hairpin RNAs and antisense oligonucleotides bind to and led to degradation of the viral RNA genome or cellular RNAs, thereby preventing their translation and viral replication. Most recently mesenchymal stem cell transplantation has been shown to possess antiviral activity in CVB3 infections. Taken together, a number of antiviral therapeutics has been developed for the treatment of myocardial CVB infection in recent years. In addition to low molecular weight inhibitors, biological therapeutics have become promising anti-viral agents.

show abstract

Cidofovir, a new approach for the treatment of cervix intraepithelial neoplasia grade III (CIN III)

et al. 2000

View full text Add to dashboard Cite

Cervix intraepithelial neoplasia grade III (CIN III) is an intraepithelial proliferative process with different levels of severity depending on both the extension of the proliferation in the epithelium and the presence of cellular atypia. Human papillomavirus (HPV) has been clearly associated with such lesions. The results of a preliminary study are described on the local application of cidofovir, an acyclic nucleoside phosphonate derivative with broad-spectrum anti-DNA virus activity for the treatment of CIN III. Cidofovir 1% in gel was applied three times, every other day, on the cervix of each of 15 women with biopsy proven CIN III. Within 1 month after the start of treatment, the cervix was removed surgically. Histology and human papillomavirus polymerase chain reaction (HPV-PCR) were carried out. In 7 of the 15 patients the histology showed a complete response, whereas 5 patients had a partial response characterized by the persistence of CIN II-III lesions, 1 patient had a dysplasia of lower grade (CIN I), and 2 patients did not show differences in the histology. Complete response was confirmed by PCR in 4 of the 7 patients, with complete response histologically. Cidofovir was not toxic to the normal epithelium. Cidofovir 1% gel was able to inhibit partially or completely cervical dysplasia lesions after only three applications (every other day). This effect was specific and tissue other than the dysplastic epithelium was not affected by the treatment.

show abstract

Antiviral activity of WIN 54954 in coxsackievirus B2 carrier state infected human myocardial fibroblasts

Cited by 13 publications

References 35 publications

Rapid routine detection of enterovirus RNA in cerebrospinal fluid by a one-step real-time RT-PCR assay

Rapid routine detection of enterovirus RNA in cerebrospinal fluid by a one-step real-time RT-PCR assay

Pharmacological and Biological Antiviral Therapeutics for Cardiac Coxsackievirus Infections

Cidofovir, a new approach for the treatment of cervix intraepithelial neoplasia grade III (CIN III)

Contact Info

Product

Resources

About